



GC Pharma(Former Green Cross Corp.)

www.globalgreencross.com

GC Pharma has been a leading biotech company for developing innovative biotherapies including vaccines, plasma-derivatives, recombinant proteins and therapeutic antibodies.

GC Pharma developed the world's first vaccine against epidemic hemorrhagic fever "Hantavax" and the world's second vaccine for varicella zoster virus vaccine "Suduvax".

GC Pharma is also pursuing opportunities in rare diseases by developing therapies such as Hunterase (world's second ERT for Hunter syndrome). In 2019, GC Pharma's total revenue rose to KRW 1.369 trillion.

Main Products

| Product Name / Active Substance | Pharmacological Effects | Exporting Countries | Remarks |
|---|---|--|---------------------|
| 1) I.V.-Globulin SN inj. / Human Intravenous Immunoglobulin | A-/Hypogammaglobulinemia Combined therapy with antibiotics for severe bacterial or viral infections Idiopathic thrombocytopenic purpura Guillain-Barre syndrome Kawasaki syndrome | Asia, Middle-East, Central & South America | Plasma Derivatives |
| 2) Albumin inj.-GCC / Human Albumin Solution | For hypoalbuminemia and shock in acute hemorrhage from loss of albumin (burns, nephrotic syndrome, etc.) and low synthesis of albumin (hepatic cirrhosis, etc.) | Asia, Middle-East, Central & South America | Plasma Derivatives |
| 3) Green-VIII inj. / Human Blood Coagulation Factor VIII | For the treatment of hemophilia A with supplies of blood coagulation factor VIII | Asia, Middle-East, Central & South America | Plasma Derivatives |
| 4) GreenGene F inj. / Recombinant Coagulation Factor VIII | For the prevention and control of bleeding episodes and preoperative management in hemophilia A | Asia, Middle-East, Central & South America | Recombinant Product |
| 5) Hepabig inj. / Human Hepatitis B Immunoglobulin | For prophylaxis of hepatitis B after exposure to HBsAg For prophylaxis of hepatitis B in neonates | Asia, Middle-East, Central & South America | Plasma Derivatives |
| 6) I.V. Hepabig inj. / Human Hepatitis B Immunoglobulin | For prevention of recurrence of hepatitis B in patients with liver transplants | Asia, Middle-East, Central & South America | Plasma Derivatives |
| 7) Sero-Tet inj. / Human Tetanus Immunoglobulin | For the prophylaxis of tetanus and the reduction of tetanus symptoms | Asia, Middle-East, Central & South America | Plasma Derivatives |
| 8) GCFLU PFS inj. / Split Virion, Trivalent Inactivated Influenza Vaccine | For the prophylaxis against influenza | Asia, Middle-East, Central & South America | Vaccines |
| 9) GCFLU Quadrivalent PFS inj. / Split Virion, Quadrivalent Inactivated Influenza Vaccine | For the prophylaxis against influenza | Asia, Middle-East, Central & South America | Vaccines |
| 10) Varicella vaccine-GCC inj. / Live Attenuated Varicella Vaccine | For the prophylaxis against varicella | Asia, Middle-East, Central & South America | Vaccines |
| 11) Hunterase / Idursulfase beta | For treatment (Enzyme Replacement Therapy) of Hunter Syndrome (Mucopolysaccharidosis II) | Asia, Middle-East, Central & South America | Recombinant Product |
| 12) Neulapeg PFS Inj. / PEG-GCSF | For decrease the duration of severe neutropenia for patients receiving cytotoxic chemotherapy for solid tumor and malignant lymphoma | Asia, Middle-East, Central & South America | Recombinant Product |

CEO
Eun-Chul Huh

Location
107, lhyeon-ro 30beon-gil,
Giheung-gu, Yongin-si, Gyeonggi-do 16924, Korea

Specialty
1. Plasma Derivatives
2. Vaccine
3. Recombinant protein

Tel / Fax / E-mail
T. 82-31-260-9300
F. 82-31-260-9491

R&D Pipeline

